Ferric derisomaltose

Ferric derisomaltose, sold under the brand name Monoferric, is a medication for the treatment of iron deficiency anemia (IDA) in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD).[1] It was approved for use in the United States in January 2020.[1][2][3] It is given intravenously.[1]

Ferric derisomaltose

Clinical data
Trade names	Monoferric
AHFS/Drugs.com	Monograph
License data	US DailyMed: Ferric_derisomaltose
Routes of administration	Intravenous (IV)
ATC code	None
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name iron(3+);(2S,3R,4R,5R)-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexane-1,2,3,4,5-pentol
CAS Number	1345510-43-1
PubChem CID	86278348
DrugBank	DB15617
UNII	AHU547PI9H
KEGG	D11808
Chemical and physical data
Formula	C18H34FeO16^+3
Molar mass	562.299 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OCC(C(C(C(CO)O)O)O)O)O)O)O)O)O)O)O.[Fe+3]
InChI InChI=1S/C18H34O16.Fe/c19-1-5(21)9(23)10(24)6(22)3-31-17-16(30)14(28)12(26)8(34-17)4-32-18-15(29)13(27)11(25)7(2-20)33-18;/h5-30H,1-4H2;/q;+3/t5-,6+,7+,8+,9+,10+,11+,12+,13-,14-,15+,16+,17-,18-;/m0./s1 Key:JTQTXQSGPZRXJF-DOJSGGEQSA-N

References

1. "Monoferric- ferric derisomaltose solution". DailyMed. 24 January 2020. Retrieved 16 February 2020.
2. "Monoferric approval letter" (PDF). U.S. Food and Drug Administration (FDA). 16 January 2020. Retrieved 16 February 2020. This article incorporates text from this source, which is in the public domain.
3. "Drug Approval Package: Monoferric Injection". U.S. Food and Drug Administration (FDA). 7 May 2020. Retrieved 13 August 2020.

External links

• "Ferric derisomaltose". Drug Information Portal. U.S. National Library of Medicine.